Tesaglitazar
Title: Tesaglitazar
CAS Registry Number: 251565-85-2
CAS Name: (aS)-a-Ethoxy-4-[2-[4-[(methylsulfonyl)oxy]phenyl]ethoxy]benzenepropanoic acid
Additional Names: (S)-2-ethoxy-3-[4-[2-(4-methanesulfonyloxyphenyl)ethoxy]phenyl]propanoic acid
Manufacturers' Codes: AZ-242
Trademarks: Galida (AstraZeneca)
Molecular Formula: C20H24O7S
Molecular Weight: 408.47
Percent Composition: C 58.81%, H 5.92%, O 27.42%, S 7.85%
Literature References: Dual-acting peroxisome proliferator-activated receptor (PPAR) a and g agonist. Prepn: K. Andersson, WO 9962872 (1999 to Astra); idem, US 6258850 (2001 to AstraZeneca). Crystal structure in complex with the PPARa and PPARg ligand binding domains: P. Cronet et al., Structure 9, 699 (2001). Solid-phase extraction LC/MS/MS determn in plasma: H. Svennberg et al., J. Chromatogr. B 787, 231 (2003). Mechanism of action study: B. D. Hegarty et al., Endocrinology 145, 3158 (2004). Clinical pharmacokinetics: H. Ericsson et al., Drug Metab. Dispos. 32, 923 (2004). Clinical effects on lipid and glucose metabolism in hypertriglyceridaemia and abdominal obesity: B. Fagerberg et al., Diabetologia 48, 1716 (2005). Review of clinical development: N. Kamber, T. M. E. Davis, IDrugs 8, 927-935 (2005).
Therap-Cat: Antidiabetic.
Keywords: Antidiabetic.

Others monographs:
α-MethyltryptamineAntimonyDifenoconazoleBenexate Hydrochloride
PheniprazineNiridazolePotassium CitrateEpoxiconazole
MeperidineTaxodioneClathratesDioscorea
MestanoloneBenzathinen-Capric AcidFlumedroxone Acetate
©2016 DrugLead US FDA&EMEA